MedicineAll countries · Checked
Survodutide: Trial Results and Expected Approval Timeline
Survodutide is Boehringer Ingelheim's once-weekly injection for obesity, and as of November 20, 2026 no country has approved it. In its 76-week phase 3 trial in adults without diabetes, weight fell by about 12% to 13% on average.
Survodutide at a glance
A glucagon and GLP-1 injection still in trials. It is not approved anywhere, so no one can be prescribed it yet.
Maker and code nameBoehringer Ingelheim, BI 456906
Doses tested in phase 33.6 mg or 6.0 mg weekly
Approval statusNot approved anywhere
From the maker and the published trials. This page is updated when a regulator decides.
Want to see what approved GLP-1 medicines cost today?
Compare GLP-1 medicine prices by countryOther medicines at a similar stage are tracked in new GLP-1 drugs.
What it isApproved?Approval dateResultsWho was in the survodutide trials?Heart safetySide effectsDosePriceSimilar drugsFAQ
What is survodutide?
Survodutide is the medicine's generic name, and BI 456906 is its development code. It has no brand name yet.
Survodutide switches on two receptors, glucagon and GLP-1. Wegovy's semaglutide targets GLP-1 only, and you can read about it in Wegovy (semaglutide).
Glucagon is a hormone involved in how the body uses energy.
It is given as an injection under the skin, once a week in the trials.
Is survodutide approved?
No. Survodutide is not approved in the US, EU, UK, Japan, Canada, Australia, Brazil, India or South Korea. Boehringer Ingelheim still calls it an investigational medicine.
That means no approved dose chart, no label and no pharmacy supply. Any page that describes it as something you can fill today is wrong.
Survodutide approval date
No approval date has been announced. A date can only follow a filing to a regulator, and we list one here only when the maker or a regulator publishes it.
We track every pending filing in new GLP-1 drugs.
Survodutide trial results
The main evidence is the SYNCHRONIZE phase 3 program. In SYNCHRONIZE-1, adults with obesity, or overweight with a related condition and no diabetes, took 3.6 mg, 6.0 mg or placebo once a week for 76 weeks.
3.6 mg−12%6.0 mg−13%Placebo−5%
These averages count everyone who was assigned the drug, including people who stopped it.
At least 5% of body weight was lost by 73% on 3.6 mg and 72% on 6.0 mg, against 46% on placebo.
Participants were 47 years old on average, with a starting BMI of 37.9, at 116 sites in 14 countries.
SYNCHRONIZE-2 tested the same two doses and placebo in 755 adults with obesity and type 2 diabetes.
These are trial averages, not a promise for any one person, and everyone in the trials also had lifestyle counseling.
Trials differ in who took part and for how long, so these numbers do not rank one medicine above another. For an approved medicine see Zepbound (tirzepatide).
Who was in the survodutide trials?
All three phase 3 trials took adults aged 18 and over, and the medicine was a once-weekly injection under the skin.
SYNCHRONIZE-1 took people with a BMI of 30 or more, or 27 or more with at least one obesity-related condition such as high blood pressure. People with diabetes were left out. You can check your own number with the BMI calculator.
SYNCHRONIZE-2 took people with a BMI of 27 or more and type 2 diabetes diagnosed at least 180 days earlier, with HbA1c from 6.5% to under 10%.
SYNCHRONIZE-CVOT took people with a BMI of 27 or more and heart disease or at least two risk factors for it, or a BMI of 30 or more with heart disease or chronic kidney disease.
The registry shows all three started in November 2023. SYNCHRONIZE-1 and SYNCHRONIZE-2 finished collecting their main data in December 2025, and SYNCHRONIZE-CVOT in June 2026.
Survodutide heart safety
SYNCHRONIZE-CVOT enrolled 5,530 adults and tested the same two doses against placebo.
It was built to check heart safety, not to prove that the drug protects the heart.
Survodutide side effects
The most common side effects were in the stomach and gut: nausea, vomiting, diarrhea and constipation.
Stomach and gut side effects were reported by 81% on 3.6 mg and 90% on 6.0 mg, against 48% on placebo. Most were mild to moderate.
There is no label yet, so there is no official side effect table or boxed warning to quote.
Survodutide dose
There is no approved dose. The phase 3 trials stepped up to a target of 3.6 mg or 6.0 mg once a week.
The trial schedule is a research plan, not a label, and it cannot be used as dosing guidance.
Doses of approved medicines are listed in GLP-1 drugs explained.
Survodutide price and generic
There is no price because the medicine is not for sale, and there is no generic.
The cost of approved GLP-1 medicines is compared in GLP-1 price by country, and generics are covered in generic GLP-1 medicines.
Survodutide and other new weight loss drugs
Other medicines at a similar stage include CagriSema, the amylin drugs in eloralintide and amycretin, and retatrutide.
The weight loss pill that is already approved is Foundayo (orforglipron).
Survodutide FAQ
Is survodutide approved?
No. No regulator in any country has approved it.
When will survodutide be available?
No date is set, because no filing date has been announced.
Does survodutide work better than Wegovy?
No head-to-head trial exists, so nobody knows. The two were tested in different trials on different people.
Is survodutide a GLP-1 drug?
Partly. It acts on the GLP-1 receptor like Wegovy does, and on the glucagon receptor as well.
Who makes survodutide?
Boehringer Ingelheim. Its code name in trial records is BI 456906.
How is survodutide taken?
In the trials it was an injection under the skin once a week. The trials did not test a pill.
How many people were in the survodutide trials?
SYNCHRONIZE-2 had 755 people and SYNCHRONIZE-CVOT had 5,530, according to the trial registry.
What dose of survodutide is used?
None is approved. The phase 3 trials aimed for 3.6 mg or 6.0 mg once a week.
Keep reading
New GLP-1 drugs and approval dates
CagriSema: trial results and FDA decision timeline
Eloralintide and amycretin in trials
This page follows the maker's announcements and the published trials, and is updated when a regulator decides. See how we check our pages.
Update log
: First published.
Sources
Boehringer Ingelheim, New phase III data in obesity and diabetes.
ClinicalTrials.gov, NCT06077864 SYNCHRONIZE-CVOT.
ClinicalTrials.gov, NCT06066528 SYNCHRONIZE-2.
American College of Cardiology, SYNCHRONIZE-1 journal scan.
ClinicalTrials.gov, NCT06066515 SYNCHRONIZE-1.
GLP1 Note is an independent information site. Which medicine suits you is for your prescriber to decide.